The trajectory of antimicrobial resistance isn’t confined to a foreboding specter of the future. This ominous reality is currently molding the contours of our approach to routine infections. As per the recent global resistance survey by the World Health Organization, we’re seeing threats mount, with one in every six ubiquitous bacterial infections eluding the once usual arsenal of drugs by 2023. The surge of resistance is noticeably pronounced in regions with fragile health ecosystems, rendering once manageable infections into stubborn adversaries. Inappropriate or unwarranted usage of antibiotics and other antimicrobials fosters a conducive environment for the bacteria to develop resistance.
In order to objectively gauge the enormity of this predicament, WHO embarked on the Global Antimicrobial Resistance and Use Surveillance System project in 2015. With the latest WHO report assimilating data from over 23 million laboratory-verified infections from 104 countries during 2023, the analysis made educated predictions that assessed resistance across eight priority bacterial pathogens. These pathogens stand guilty for bloodstream, gastrointestinal, urinary tract infections, and gonorrhoea.
The survey unveiled that antibiotic resistance, especially among gram-negative bacteria, known for its resilient outer covering, is not just pervading across the globe but experiencing a rapid surge. More tragically, it underscores the disproportionate burden on low and middle-income countries with constrained diagnostic potential, limited surveillance coverage, and restrained access to effective antibiotics. The amalgamation of resistance and weak health infrastructure inflicts double jeopardy on these vulnerable demographics.
The data demarcated specific geographical contours of resistance, with Southeast Asia and the Eastern Mediterranean echoing the heightened alarms of drug resistance, eroding the efficacy of standard treatments in one-third of the infections. Africa, Europe, and the Western Pacific are not trailing far behind with resistance in every fifth and tenth infection.
The set of infections exhibiting significant resistance expands to urinary tract infections, bloodstream infections, and gastrointestinal infections, with highest resistances observed for urinary tract. However, drug-resistant bacteria, like Klebsiella pneumoniae and Acinetobacter, are becoming notorious contributors to hospital-acquired infections. On the other hand, resilient variants of Escherichia coli and methicillin-resistant Staphylococcus aureus are posing formidable challenges.
In response to this escalating crisis, the report proposes some actionable strategies, revolving around strengthening monitoring systems, enhancing diagnostic capabilities, and innovating in antibiotics usage paradigm. By 2030, WHO envisages a marked shift with 70% of prescribed antibiotics being derived from the safer ‘Access’ group and curtailed dependence on ‘Watch’ antibiotics that catalyze resistance when overutilized. Furthermore, the report champions improved preventive measures, constructive research and development, and inclusive health coverage expansion. It stresses the importance of universal health coverage, advanced social protection, and resilient healthcare services to shield the most susceptible segments from these drug-resistant infections.